Abstract:Background Early-onset androgenetic alopecia (AGA) has been associated with various chronic conditions, including metabolic syndrome (MetS). Gaining a deep understanding of early-onset AGA may enable earlier intervention in individuals at high risks. This scoping review aims to explore the risk factors and etiology, associated conditions, and adverse effects on wellbeing in early-onset AGA. Methods Electronic literature searches were conducted in MEDLINE, EMBASE and CENTRIAL. Eligible studies included case-control, cohort, cross-sectional, and meta-analysis studies. Selected studies needed to clearly define early-onset AGA cases or include only cases starting before the age of 40 and compare them with appropriate controls. The exclusion criteria comprised editorials, commentaries, case series, and non-systematic reviews, among others. Data extraction involved collecting study characteristics, methodologies, main outcomes, and findings. Descriptive tables were used to summarize key information and relevant variables when necessary. Results Among the 65 eligible articles, 67.69% were case-control studies and 78.46% evaluated only male patients. “Early-onset” was defined as cases developing before the age of 30 years in 43.08% of the studies. The Hamilton–Norwood scale was the most frequently used method for evaluating the severity of alopecia in men (69.23%). Reported risk factors for early-onset AGA included a family history of AGA, cigarette smoking, unhealthy dietary habits, and a high body mass index. Early-onset AGA may also be associated with hormonal profiles, 5α-reductase enzyme activity, androgen receptor genes, and some susceptibility loci. Comorbidities investigated included MetS, cardiovascular disease, insulin resistance, dyslipidemia, and Parkinson’s disease. Men with early-onset AGA may have reduced treatment efficacy with drug like rosuvastatin, metformin or lisinopril for dyslipidemia, prediabetes, or hypertension. Additionally, young men with AGA tended to suffer from psychological issues such as anxiety and low self-esteem compared to those without hair loss. Conclusion Early-onset AGA is a complex condition with various risk factors and etiology, associated comorbidities, and potential implications for treatment response and psychological health.

A review of genetic researches of and rogenic alopcia

Serum Levels of Androgen-Associated Hormones Are Correlated with Curative Effect in Androgenic Alopecia in Young Men

Androgen Receptor Expression in Male Pattern Baldness Patients

Androgenetic Alopecia: A Review

Androgenetic Alopecia in Men: An Update On Genetics

Androgenetic alopecia: An update

How to treat androgenetic alopecia – the most common form of hair loss. A review

Expression of BMP type IA receptor in the scalp of AGA patients

Androgenetic Alopecia: Therapy Update

Molecular mechanisms of androgenetic alopecia

Recent advances in the genetics of alopecia areata

Alopecia Areata: An Overview of the Disease and its Genetic Basis: Review Article

The Therapeutic Progress of Androgenetic Alopecia

A Focus on Androgenetic Alopecia

Analysis of influencing factors to the therapeutic effect of androgenetic alopecia

Relation between dermal papilla cells and androgenetic alopecia

Analysis of Familial History in Chinese Patients with Androgenetic Alopecia

Thyroid receptor β: A promising target for developing novel anti-androgenetic alopecia drugs

Factors associated with early-onset androgenetic alopecia: A scoping review

Application of multi-omics techniques to androgenetic alopecia: current status and perspectives

A review of the treatment of male pattern hair loss